Chemotherapy plus targeted drugs for older adults with HER2-positive breast cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a combination of three drugs—trastuzumab and pertuzumab (which target HER2 protein on cancer cells) plus a low-dose chemotherapy called vinorelbine—given before surgery in people aged 70 and older with HER2-positive breast cancer. The goal is to shrink the tumor so surgery is more effective while being gentler on older patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years old or older
- You have HER2-positive breast cancer confirmed by biopsy with a tumor larger than 2 cm or cancer in lymph nodes
- Your cancer has not spread to distant parts of your body (stage IV)
- You have never received chemotherapy, hormone therapy, or HER2-targeted drugs before
- Your heart function, liver, kidneys, and blood counts are healthy enough for treatment
- You have no uncontrolled high blood pressure, serious heart disease, or active infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two antibody drugs (trastuzumab and pertuzumab) plus a targeted pill (olaparib) given before surgery to treat elderly women with HER2-positive breast cancer. The goal is to see if this approach helps shrink tumors or eliminate them entirely before surgery.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests whether giving a combination of two targeted drugs (pyrotinib and trastuzumab) along with standard chemotherapy before surgery can work better for HER2-positive breast cancer. It is for women whose cancer has not spread to distant organs and who have not yet had treatment for their cancer.
This trial tests whether a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) works well for women 65 and older with early-stage HER2-negative breast cancer. The goal is to maintain effectiveness while reducing side effects in this group.
This trial tests a combination of targeted drugs (Initumab and Pyrrotinib) plus chemotherapy before surgery for HER2-positive breast cancer. It compares different treatment lengths to see which is more effective and safe.
Hear when a new Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.